341 related articles for article (PubMed ID: 36325453)
1. Silent pheochromocytoma and paraganglioma: Systematic review and proposed definitions for standardized terminology.
Constantinescu G; Preda C; Constantinescu V; Siepmann T; Bornstein SR; Lenders JWM; Eisenhofer G; Pamporaki C
Front Endocrinol (Lausanne); 2022; 13():1021420. PubMed ID: 36325453
[TBL] [Abstract][Full Text] [Related]
2. Surgical strategies of complicated pheochromocytomas/paragangliomas and literature review.
Wang X; Zhao Y; Liao Z; Zhang Y
Front Endocrinol (Lausanne); 2023; 14():1129622. PubMed ID: 37152961
[TBL] [Abstract][Full Text] [Related]
3. Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas.
Mete O; Asa SL; Gill AJ; Kimura N; de Krijger RR; Tischler A
Endocr Pathol; 2022 Mar; 33(1):90-114. PubMed ID: 35285002
[TBL] [Abstract][Full Text] [Related]
4. Pediatric Metastatic Pheochromocytoma and Paraganglioma: Clinical Presentation and Diagnosis, Genetics, and Therapeutic Approaches.
Kuo MJM; Nazari MA; Jha A; Pacak K
Front Endocrinol (Lausanne); 2022; 13():936178. PubMed ID: 35903274
[TBL] [Abstract][Full Text] [Related]
5. New Insights into the Nuclear Imaging Phenotypes of Cluster 1 Pheochromocytoma and Paraganglioma.
Taïeb D; Pacak K
Trends Endocrinol Metab; 2017 Nov; 28(11):807-817. PubMed ID: 28867159
[TBL] [Abstract][Full Text] [Related]
6. Diagnosis and Management of Pheochromocytomas and Paragangliomas: A Guide for the Clinician.
Sharma S; Fishbein L
Endocr Pract; 2023 Dec; 29(12):999-1006. PubMed ID: 37586639
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-6 producing pheochromocytoma/paraganglioma: case series from a tertiary referral centre for pheochromocytomas and paragangliomas.
Meijs AC; Schroijen MA; Snel M; Corssmit EPM
J Endocrinol Invest; 2021 Oct; 44(10):2253-2259. PubMed ID: 33715142
[TBL] [Abstract][Full Text] [Related]
8. Clinical differences between small and large pheochromocytomas and paragangliomas.
Zhao L; Li Z; Meng X; Fan H; Zhang Z; Zhang Z; Liu Y; Zhou X; Zhu H
Front Endocrinol (Lausanne); 2023; 14():1087506. PubMed ID: 36967797
[TBL] [Abstract][Full Text] [Related]
9. Germline DLST Variants Promote Epigenetic Modifications in Pheochromocytoma-Paraganglioma.
Buffet A; Zhang J; Rebel H; Corssmit EPM; Jansen JC; Hensen EF; Bovée JVMG; Morini A; Gimenez-Roqueplo AP; Hes FJ; Devilee P; Favier J; Bayley JP
J Clin Endocrinol Metab; 2021 Jan; 106(2):459-471. PubMed ID: 33180916
[TBL] [Abstract][Full Text] [Related]
10. Multidisciplinary practice guidelines for the diagnosis, genetic counseling and treatment of pheochromocytomas and paragangliomas.
Garcia-Carbonero R; Matute Teresa F; Mercader-Cidoncha E; Mitjavila-Casanovas M; Robledo M; Tena I; Alvarez-Escola C; Arístegui M; Bella-Cueto MR; Ferrer-Albiach C; Hanzu FA
Clin Transl Oncol; 2021 Oct; 23(10):1995-2019. PubMed ID: 33959901
[TBL] [Abstract][Full Text] [Related]
11. Hemodynamic instability during percutaneous ablation of extra-adrenal metastases of pheochromocytoma and paragangliomas: a case series.
Deljou A; Kohlenberg JD; Weingarten TN; Bancos I; Young WF; Schroeder DR; Martin DP; Sprung J
BMC Anesthesiol; 2018 Nov; 18(1):158. PubMed ID: 30400849
[TBL] [Abstract][Full Text] [Related]
12. Pheochromocytoma and paraganglioma: clinical feature-based disease probability in relation to catecholamine biochemistry and reason for disease suspicion.
Geroula A; Deutschbein T; Langton K; Masjkur J; Pamporaki C; Peitzsch M; Fliedner S; Timmers HJLM; Bornstein SR; Beuschlein F; Stell A; Januszewicz A; Prejbisz A; Fassnacht M; Lenders JWM; Eisenhofer G
Eur J Endocrinol; 2019 Oct; 181(4):409-420. PubMed ID: 31370000
[TBL] [Abstract][Full Text] [Related]
13. Familial pheochromocytomas and paragangliomas.
King KS; Pacak K
Mol Cell Endocrinol; 2014 Apr; 386(1-2):92-100. PubMed ID: 23933153
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis of endocrine disease: Biochemical diagnosis of phaeochromocytoma and paraganglioma.
van Berkel A; Lenders JW; Timmers HJ
Eur J Endocrinol; 2014 Mar; 170(3):R109-19. PubMed ID: 24347425
[TBL] [Abstract][Full Text] [Related]
15. Risk of complications after core needle biopsy in pheochromocytoma/paraganglioma.
Zhang L; Åkerström T; Mollazadegan K; Beuschlein F; Pacak K; Skogseid B; Crona J
Endocr Relat Cancer; 2023 Jul; 30(7):. PubMed ID: 37185155
[TBL] [Abstract][Full Text] [Related]
16. Pathophysiology and Management of Glycemic Alterations before and after Surgery for Pheochromocytoma and Paraganglioma.
Lopez C; Bima C; Bollati M; Bioletto F; Procopio M; Arata S; Candela DG; Beccuti G; Ghigo E; Maccario M; Parasiliti-Caprino M
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982228
[TBL] [Abstract][Full Text] [Related]
17. Pheochromocytoma/paraganglioma crisis: case series from a tertiary referral center for pheochromocytomas and paragangliomas.
Meijs AC; Snel M; Corssmit EPM
Hormones (Athens); 2021 Jun; 20(2):395-403. PubMed ID: 33575936
[TBL] [Abstract][Full Text] [Related]
18. [Diagnostic approach of pheochromocytomas and paragangliomas].
Gómez RM; Hernaiz M; de Miguel V; Aparicio LS; Marín MJ; Lupi S; Barontini M;
Hipertens Riesgo Vasc; 2019; 36(1):34-43. PubMed ID: 30078655
[TBL] [Abstract][Full Text] [Related]
19. Genetic Analysis and Clinical Characteristics of Hereditary Pheochromocytoma and Paraganglioma Syndrome in Korean Population.
Choi H; Kim KJ; Hong N; Shin S; Choi JR; Kang SW; Lee ST; Rhee Y
Endocrinol Metab (Seoul); 2020 Dec; 35(4):858-872. PubMed ID: 33397040
[TBL] [Abstract][Full Text] [Related]
20. Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography.
Timmers HJ; Chen CC; Carrasquillo JA; Whatley M; Ling A; Eisenhofer G; King KS; Rao JU; Wesley RA; Adams KT; Pacak K
J Natl Cancer Inst; 2012 May; 104(9):700-8. PubMed ID: 22517990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
